Monday, March 23, 2026 12:18:20 AM
I agree with your timing analysis. One thing I would add is the ECA guidance timing.
Obviously the MHRA CAN approve before the final guidance is released, but with this being a first-of-its-kind approval (external controls + a personalized cell therapy), MHRA may to wait until the new framework is in place to protect themselves and make DCVax the first approval clearly operating under the new rules.NWBO basically stated this in their June 30, 2025 10-Q:If the science was effectively settled at the Nov 2025 CHM, it wouldn't be surprising if the final administrative step lines up with the April 28, 2026 (or before) ECA guidance effective date.Your CHM timing comps + this regulatory timing both point to the same window and I don’t think that it is a coincidence That the MHRA is taking all of its statutorily allotted time. Maybe NWBO itself, or at least GZ in his comments to me and other shareholders about being MORE FRUSTRATED THAN ANYONE, doesn’t realize that the MHRA is essentially stalling until final ECA guidance is released.GLTA
Obviously the MHRA CAN approve before the final guidance is released, but with this being a first-of-its-kind approval (external controls + a personalized cell therapy), MHRA may to wait until the new framework is in place to protect themselves and make DCVax the first approval clearly operating under the new rules.NWBO basically stated this in their June 30, 2025 10-Q:If the science was effectively settled at the Nov 2025 CHM, it wouldn't be surprising if the final administrative step lines up with the April 28, 2026 (or before) ECA guidance effective date.Your CHM timing comps + this regulatory timing both point to the same window and I don’t think that it is a coincidence That the MHRA is taking all of its statutorily allotted time. Maybe NWBO itself, or at least GZ in his comments to me and other shareholders about being MORE FRUSTRATED THAN ANYONE, doesn’t realize that the MHRA is essentially stalling until final ECA guidance is released.GLTA
Bullish
Recent NWBO News
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
